Kura Oncology to Report Third Quarter 2021 Financial Results

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) will release its third quarter 2021 financial results on November 4, 2021, after U.S. markets close. A webcast and conference call, scheduled for 4:30 p.m. ET / 1:30 p.m. PT, will provide financial insights and a corporate update. The call can be accessed by domestic and international callers with specific dial-in information. Kura focuses on innovative cancer treatments, including KO-539 for AML and Tipifarnib for HRAS mutant HNSCC, highlighting its commitment to precision medicine.

Positive

• Kura's pipeline includes KO-539, currently in Phase 1b for relapsed/refractory AML.
• Tipifarnib has received Breakthrough Therapy Designation for HRAS mutant HNSCC.

Negative

• None.

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (866) 269-4260 for domestic callers and (323) 347-3277 for international callers and entering the conference code: 9395801. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC. The Company is also developing KO-2806, a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What are the key financial results for Kura Oncology in Q3 2021?

Kura Oncology will announce its Q3 2021 financial results on November 4, 2021.

When will Kura Oncology host its financial results conference call?

Kura Oncology will host a conference call on November 4, 2021, at 4:30 p.m. ET.

What is Kura Oncology's primary focus in cancer treatment?

Kura Oncology focuses on precision medicines targeting cancer signaling pathways.

What are the current trials involving Kura's drug candidates?

Kura's KO-539 is in a Phase 1b trial for AML, while Tipifarnib is in a registration-directed study for HRAS mutant HNSCC.